☰

Tracy R. Daniels, Ph.D. - Publications

Affiliations: 
2004 Loma Linda University, Loma Linda, United States 
Area:
Cell Biology, Oncology
Tree Info Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2012 Daniels TR, Martínez-Maza O, Penichet ML. Animal models for IgE-meditated cancer immunotherapy. Cancer Immunology, Immunotherapy : Cii. 61: 1535-46. PMID 22193986 DOI: 10.1007/S00262-011-1169-1  0.353
2012 Daniels TR, Leuchter RK, Quintero R, Helguera G, Rodríguez JA, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet ML. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunology, Immunotherapy : Cii. 61: 991-1003. PMID 22127364 DOI: 10.1007/S00262-011-1150-Z  0.374
2012 Daniels TR, Bernabeu E, Rodríguez JA, Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Helguera G, Penichet ML. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochimica Et Biophysica Acta. 1820: 291-317. PMID 21851850 DOI: 10.1016/J.Bbagen.2011.07.016  0.329
2011 Rodríguez JA, Luria-Pérez R, López-Valdés HE, Casero D, Daniels TR, Patel S, Avila D, Leuchter R, So S, Ortiz-Sánchez E, Bonavida B, Martínez-Maza O, Charles AC, Pellegrini M, Helguera G, et al. Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. Leukemia & Lymphoma. 52: 2169-78. PMID 21870996 DOI: 10.3109/10428194.2011.596964  0.336
2011 Daniels TR, Ortiz-Sánchez E, Luria-Pérez R, Quintero R, Helguera G, Bonavida B, Martínez-Maza O, Penichet ML. An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 500-8. PMID 21654517 DOI: 10.1097/Cji.0B013E318222Ffc8  0.326
2011 Daniels TR, Ortiz-Sanchez E, Luria-Perez R, Quintero R, Helguera G, Bonavida B, Martinez-Maza O, Penichet ML. Abstract 3622: An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of multiple myeloma Cancer Research. 71: 3622-3622. DOI: 10.1158/1538-7445.Am2011-3622  0.341
2011 Leoh LS, Mediavilla-Varela M, Basu A, Daniels TR, Martinez S, Pacheco FJ, Padilla A, Asuelime G, Rios-Colon L, Leon MD, Casiano CA. Abstract 2083: The stress oncoprotein LEDGF/p75 attenuates oxidative stress-induced necrosis but not apoptosis in prostate cancer cells Cancer Research. 71: 2083-2083. DOI: 10.1158/1538-7445.Am2011-2083  0.603
2010 Daniels TR, Neacato II, Rodríguez JA, Pandha HS, Morgan R, Penichet ML. Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Leukemia. 24: 1555-65. PMID 20574452 DOI: 10.1038/Leu.2010.142  0.432
2010 Suzuki E, Daniels TR, Helguera G, Penichet ML, Umezawa K, Bonavida B. Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. International Journal of Oncology. 36: 1299-307. PMID 20372806 DOI: 10.3892/Ijo_00000615  0.386
2010 Luria-Perez R, Helguera GF, Quintero R, Cruz ALD, Rodriguez JA, Daniels TR, Penichet ML. Abstract LB-304: Novel antibody-(IL-12) fusion proteins with disrupted heparin-binding activity for the therapy of cancer Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-304  0.322
2010 Rodríguez JA, López-Valdes HE, Helguera GF, So S, Luria-Pérez R, Daniels TR, Charles AC, Penichet ML. Abstract 4456: Molecular events required for the induction of lethal iron deprivation in malignant hematopoietic cells via an antibody-avidin fusion protein specific for human transferrin receptor 1 Cancer Research. 70: 4456-4456. DOI: 10.1158/1538-7445.Am10-4456  0.343
2009 Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A, Wall NR, Lilly MB, De Leon M, Casiano CA. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Molecular Cancer. 8: 68. PMID 19715609 DOI: 10.1186/1476-4598-8-68  0.675
2008 Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. Journal of Immunology (Baltimore, Md. : 1950). 180: 6199-210. PMID 18424742 DOI: 10.4049/Jimmunol.180.9.6199  0.459
2008 Ortiz-Sánchez E, Helguera G, Daniels TR, Penichet ML. Antibody-cytokine fusion proteins: applications in cancer therapy. Expert Opinion On Biological Therapy. 8: 609-32. PMID 18407765 DOI: 10.1517/14712598.8.5.609  0.303
2008 Suzuki E, Umezawa K, Helguera G, Daniels TR, Schiller G, Berenson JR, Penichet ML, Bonavida B. Inhibition of the Akt Pathway in MM Cell Lines by the Anti-TfR-IgG3-Avidin Fusion Protein (Anti-TfR-IgG3-Av): Role in Chemosensitization to CDDP-Induced Apoptosis Blood. 112: 4473-4473. DOI: 10.1182/Blood.V112.11.4473.4473  0.438
2008 Rodriguez JA, Helguera G, Daniels TR, Diaz-Cano DC, Ortiz-Sanchez E, Coppola G, Pellegrini M, Martinez-Maza O, Penichet ML. Cellular and Molecular Mechanisms of Sensitivity and Resistance of Hematopoietic Malignant Cells to Treatment with ch128.1Av, An Antibody-Avidin Fusion Protein Specific for Human Transferrin Receptor 1 (CD71). Blood. 112: 1608-1608. DOI: 10.1182/Blood.V112.11.1608.1608  0.356
2007 Daniels TR, Ng PP, Delgado T, Lynch MR, Schiller G, Helguera G, Penichet ML. Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Molecular Cancer Therapeutics. 6: 2995-3008. PMID 18025284 DOI: 10.1158/1535-7163.Mct-07-0330  0.377
2007 Rodríguez JA, Helguera G, Daniels TR, Neacato II, López-Valdés HE, Charles AC, Penichet ML. Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor. Journal of Controlled Release : Official Journal of the Controlled Release Society. 124: 35-42. PMID 17884229 DOI: 10.1016/J.Jconrel.2007.08.020  0.344
2007 Helguera G, Rodríguez JA, Daniels TR, Penichet ML. Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies. Cancer Immunology, Immunotherapy : Cii. 56: 1507-12. PMID 17310381 DOI: 10.1007/S00262-007-0297-0  0.308
2007 Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A. Targeting aurora kinases as therapy in multiple myeloma. Blood. 109: 3915-21. PMID 17213289 DOI: 10.1182/Blood-2006-07-037671  0.418
2007 Ortiz-Sanchez E, Daniels TR, Helguera G, Martinez-Maza O, Bonavida B, Penichet ML. The Role of Iron in the Cytotoxicity Induced in Hematopoietic Malignant Cell Lines by an Anti-Transferrin Receptor IgG3-Avidin Fusion Protein and Gambogic Acid. Blood. 110: 4204-4204. DOI: 10.1182/Blood.V110.11.4204.4204  0.41
2007 Helguera G, Rodriguez JA, Daniels TR, Diaz-Cano DC, Pellegrini M, Penichet ML. Insights into the Genetic Signature Associated with Cell Death Induced by an Antibody-Avidin Fusion Protein Specific for Transferrin Receptor. Blood. 110: 3476-3476. DOI: 10.1182/Blood.V110.11.3476.3476  0.427
2006 Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clinical Immunology (Orlando, Fla.). 121: 159-76. PMID 16920030 DOI: 10.1016/J.Clim.2006.06.006  0.377
2006 Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clinical Immunology (Orlando, Fla.). 121: 144-58. PMID 16904380 DOI: 10.1016/J.Clim.2006.06.010  0.393
2006 Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet ML. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood. 108: 2745-54. PMID 16804109 DOI: 10.1182/Blood-2006-04-020263  0.476
2005 Pacheco FJ, Servin J, Dang D, Kim J, Molinaro C, Daniels T, Brown-Bryan TA, Imoto-Egami M, Casiano CA. Involvement of lysosomal cathepsins in the cleavage of DNA topoisomerase I during necrotic cell death. Arthritis and Rheumatism. 52: 2133-45. PMID 15986368 DOI: 10.1002/Art.21147  0.658
2005 Shi FD, Zhang JY, Liu D, Rearden A, Elliot M, Nachtsheim D, Daniels T, Casiano CA, Heeb MJ, Chan EK, Tan EM. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. The Prostate. 63: 252-8. PMID 15538718 DOI: 10.1002/Pros.20181  0.722
2005 Daniels T, Zhang J, Gutierrez I, Elliot ML, Yamada B, Heeb MJ, Sheets SM, Wu X, Casiano CA. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. The Prostate. 62: 14-26. PMID 15389814 DOI: 10.1002/Pros.20112  0.726
2003 Ganapathy V, Daniels T, Casiano CA. LEDGF/p75: a novel nuclear autoantigen at the crossroads of cell survival and apoptosis. Autoimmunity Reviews. 2: 290-7. PMID 12965181 DOI: 10.1016/S1568-9972(03)00063-6  0.714
2002 Wu X, Daniels T, Molinaro C, Lilly MB, Casiano CA. Caspase cleavage of the nuclear autoantigen LEDGF/p75 abrogates its pro-survival function: implications for autoimmunity in atopic disorders. Cell Death and Differentiation. 9: 915-25. PMID 12181742 DOI: 10.1038/Sj.Cdd.4401063  0.717
Show low-probability matches.